EXEL Stock Cash Flow Statements

Exelixis Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Exelixis Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-09-30

net income	184,848,000	159,616,000	139,861,000	117,973,000	226,116,000	37,317,000	85,518,000	1,041,000	81,178,000	40,028,000	-30,173,000	73,210,000	70,672,000	68,573,000	95,166,000	38,204,000	96,092,000	1,601,000	28,388,000	-32,040,000	66,821,000	48,612,000	68,743,000	97,452,000	79,042,000	75,775,000	360,089,000	126,630,000	87,494,000	115,857,000	38,489,000	81,382,000	17,656,000	16,700,000	35,123,000	-6,983,000	-37,015,000	-61,347,000	-43,641,000	-47,564,000	-43,362,000	-35,170,000	-57,953,000	-62,560,000	-73,410,000	-74,619,000	-70,746,000	-67,124,000	-62,161,000	-44,729,000	-52,193,000	-32,814,000	-36,487,000	-26,151,000				-27,490,000									-37,949,000	-38,507,000	-45,124,000	-41,274,000	-19,922,000	-13,696,000	-28,562,000	-24,201,000	-25,182,000	-25,197,000	-23,990,000	-27,123,000	-24,522,000	-22,775,000	-9,696,000	-27,411,000	-51,922,000			-28,843,000	-24,995,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	7,342,000	7,345,000										5,663,000												2,090,000	2,036,000	1,962,000	2,039,000	1,700,000	805,000	371,000	345,000	279,000	282,000	281,000	248,000	298,000	227,000	229,000	343,000	379,000	387,000	297,000	-623,000	1,921,000	595,000	498,000	765,000	754,000	786,000	842,000	1,646,000	1,431,000	1,407,000	1,233,000	1,787,000	1,106,000	2,000,000	1,929,000	2,267,000	2,403,000	2,801,000	3,072,000	3,037,000	3,117,000	3,155,000	3,286,000	3,405,000	3,261,000	3,297,000	3,264,000	3,142,000	2,847,000	2,384,000	2,757,000	3,524,000	3,893,000	4,360,000	4,313,000	4,115,000	4,298,000	4,078,000	4,178,000	4,173,000	3,967,000	4,097,000	4,478,000	4,180,000
stock-based compensation	36,071,000	25,930,000	26,346,000	23,023,000	25,354,000	19,113,000	24,306,000	40,478,000	24,900,000	16,661,000	25,856,000	37,337,000	24,622,000	19,759,000	23,166,000	33,966,000	28,035,000	34,653,000	19,279,000	55,655,000	16,154,000	13,982,000	15,855,000	13,139,000	15,079,000	12,529,000	12,296,000	9,742,000	9,283,000	9,305,000
non-cash lease expense	6,070,000	6,096,000	6,350,000	7,168,000	7,179,000	6,764,000	7,501,000	7,495,000	7,249,000	6,731,000	6,384,000	5,488,000	5,058,000	1,385,000	1,380,000	1,366,000	1,365,000	1,221,000	1,223,000	1,224,000	1,209,000	1,174,000
acquired in-process research and development technology			19,500,000	11,000,000	750,000	19,500,000	0	91,000,000	1,000,000	36,500,000
other	-5,831,000	-4,786,000	-4,379,000	-17,171,000	-1,282,000	9,206,000	-4,425,000	-4,196,000	-4,433,000	-3,743,000	-7,915,000	3,031,000	2,779,000	1,580,000	-12,428,000	13,040,000	16,253,000	6,578,000	1,426,000	883,000	1,614,000	-888,000					-935,000	-933,000	-2,212,000	1,722,000	59,000	384,000	466,000	680,000	-1,129,000	-243,000	336,000	-1,474,000	-11,000	245,000	456,000	637,000	559,000	987,000	1,140,000	1,475,000	1,544,000	1,601,000	1,909,000	1,733,000	1,539,000	1,084,000	1,062,000	1,304,000	1,164,000	1,855,000	1,304,000	478,000	819,000	762,000	715,000	938,000	998,000	426,000	-161,000	356,000	-63,000	417,000	380,000	212,000	240,000	229,000	172,000	145,000	202,000	242,000	175,000	135,000	156,000	157,000	172,000	117,000	203,000	173,000	-508,000	562,000	134,000
changes in operating assets and liabilities:
trade receivables	-10,718,000	-16,119,000		127,025,000	-156,047,000	-3,170,000	11,181,000	-15,487,000	861,000	-19,178,000	-41,000	20,197,000	-45,100,000	91,793,000	-102,200,000	-7,811,000	5,377,000	-17,690,000	4,604,000	-45,060,000	16,256,000	-18,270,000	50,733,000	-72,247,000	10,129,000	55,101,000
inventory	2,639,000	-71,000	2,762,000	-384,000	1,360,000	1,715,000	1,526,000	-1,688,000	-4,445,000	-8,370,000	-1,847,000	-1,514,000	-4,802,000	-3,520,000	13,747,000	-18,936,000	-5,930,000	-2,090,000	-8,431,000	-6,417,000	-2,354,000	-4,695,000	-2,203,000	-1,014,000	-2,209,000	-305,000	595,000	-2,062,000	-808,000	-906,000	-851,000	-381,000	-2,121,000	34,000	-46,000	-484,000	-336,000	144,000	-494,000	486,000	-15,000	-212,000	1,495,000	-850,000	-340,000	204,000	-1,126,000	-1,083,000	-401,000	-280,000
prepaid expenses and other assets	-104,706,000	20,320,000	94,147,000	-96,728,000	23,585,000	10,075,000	-32,254,000	-6,118,000	-1,824,000	10,372,000	6,907,000	-9,141,000	-22,420,000	-3,605,000	-15,623,000	-11,956,000	-14,168,000	1,872,000	-9,963,000	3,086,000	-16,091,000	-2,863,000																		-1,061,000	2,799,000	-1,846,000		-3,060,000
accrued collaboration liabilities	-3,964,000	4,605,000	854,000	1,347,000	1,479,000	-3,829,000	264,000	-2,191,000	5,136,000	-1,864,000	1,911,000	-11,713,000	998,000	-54,261,000															-261,000	-1,000,000	-163,000	1,218,000
accounts payable and other liabilities	-63,508,000	8,501,000	2,243,000	26,393,000	-16,275,000	-34,247,000	46,777,000	192,000	5,154,000	1,123,000	19,127,000	-11,188,000	10,527,000	7,376,000	7,278,000	18,977,000	28,697,000	138,000	-42,000	50,889,000	2,393,000	-2,131,000
net cash from operating activities	48,993,000	211,437,000	240,263,000	271,338,000	119,548,000	68,822,000	10,571,000	117,367,000	120,978,000	84,408,000	73,694,000	110,071,000	31,130,000	147,719,000	96,452,000	83,307,000	181,501,000	39,544,000	33,293,000	17,938,000	101,677,000	56,074,000	158,021,000	75,614,000	131,728,000	161,593,000	104,591,000	164,552,000	74,769,000	71,808,000	53,353,000	37,865,000	5,535,000	68,858,000	83,714,000	-6,435,000	-25,879,000	154,896,000	-35,433,000	-34,233,000	-26,833,000	-45,086,000	-49,976,000	-58,006,000	-55,337,000	-72,086,000	-47,329,000	-56,995,000	-40,034,000	-54,415,000	-38,736,000	-34,053,000	-35,391,000	-14,966,000	-29,174,000	-43,267,000	-43,516,000	-43,276,000	21,254,000	-43,827,000	-24,736,000	-53,739,000	-50,750,000	90,706,000	-12,425,000	-42,122,000	153,821,000	-56,391,000	-67,969,000	-39,218,000	-24,914,000	-39,356,000	-49,269,000	44,800,000	10,124,000	-34,251,000	-31,246,000	10,034,000	-6,177,000	-32,645,000	24,746,000	-32,285,000
capex	-2,838,000	-2,952,000	-3,977,000	-8,197,000	-6,570,000	-9,691,000	-13,135,000	-9,373,000	-5,937,000	-12,024,000	-1,717,000	-9,970,000	-12,337,000	-5,609,000	-18,364,000	-14,479,000	-20,211,000	-13,557,000	-14,291,000	-6,091,000	-6,641,000	-2,480,000	0	-2,059,000	-1,209,000	-2,307,000	0	-15,221,000	-12,235,000	-2,947,000	-17,694,000	-1,137,000	-1,504,000	-808,000	-587,000	-33,000	-401,000	-682,000	-333,000	-20,000	-63,000	-31,000	-22,000	-108,000	40,000	-384,000	-92,000	-677,000	-673,000	-729,000	-1,189,000	-1,019,000	-437,000	-72,000	-279,000	-144,000	-163,000	-405,000	-330,000	-650,000	-579,000	-252,000	-4,316,000	-750,000	-444,000	-398,000	-1,207,000	-2,391,000	-6,171,000	-5,363,000	-3,249,000	-4,749,000	-5,761,000	-3,640,000	-3,273,000	-1,540,000	-4,740,000	-2,057,000	-3,238,000	-2,859,000	-4,274,000	-3,986,000
free cash flows	46,155,000	208,485,000	236,286,000	263,141,000	112,978,000	59,131,000	-2,564,000	107,994,000	115,041,000	72,384,000	71,977,000	100,101,000	18,793,000	142,110,000	78,088,000	68,828,000	161,290,000	25,987,000	19,002,000	11,847,000	95,036,000	53,594,000	158,021,000	73,555,000	130,519,000	159,286,000	104,591,000	149,331,000	62,534,000	68,861,000	35,659,000	36,728,000	4,031,000	68,050,000	83,127,000	-6,468,000	-26,280,000	154,214,000	-35,766,000	-34,253,000	-26,896,000	-45,117,000	-49,998,000	-58,114,000	-55,297,000	-72,470,000	-47,421,000	-57,672,000	-40,707,000	-55,144,000	-39,925,000	-35,072,000	-35,828,000	-15,038,000	-29,453,000	-43,411,000	-43,679,000	-43,681,000	20,924,000	-44,477,000	-25,315,000	-53,991,000	-55,066,000	89,956,000	-12,869,000	-42,520,000	152,614,000	-58,782,000	-74,140,000	-44,581,000	-28,163,000	-44,105,000	-55,030,000	41,160,000	6,851,000	-35,791,000	-35,986,000	7,977,000	-9,415,000	-35,504,000	20,472,000	-36,271,000
cash flows from investing activities:
purchases of marketable securities	-101,485,000	-186,701,000	-305,383,000																																																	-199,303,000	-46,853,000	-113,368,000	-26,633,000	-21,144,000	-129,421,000	-60,015,000	-26,131,000	-37,623,000	-80,000,000	-23,563,000	-39,277,000	-78,869,000	-38,972,000	-4,048,000	3,665,000	3,660,000	-4,347,000	-4,932,000	-30,726,000	-64,897,000	-46,638,000	-61,556,000	-55,143,000	-8,598,000	-12,821,000	-15,180,000
proceeds from maturities and sales of marketable securities	353,104,000	258,917,000	226,159,000
purchases of property, equipment and other	-2,838,000	-2,952,000	-3,977,000	-8,197,000	-6,570,000	-9,691,000	-13,135,000	-9,373,000	-5,937,000	-12,024,000	-1,717,000	-8,043,000	-12,337,000	-5,609,000	-15,960,000	-14,497,000	-20,211,000	-13,557,000	-14,290,000	-6,130,000	-6,964,000	-2,961,000
net cash from investing activities	248,031,000	49,764,000	-93,201,000	-217,147,000	81,772,000	111,793,000	61,737,000	34,685,000	-73,785,000	-49,592,000	-245,782,000	-68,951,000	-135,142,000	-74,539,000	-13,055,000	-21,239,000	-70,845,000	62,255,000	-29,509,000	-207,600,000	73,274,000	32,620,000	-130,201,000	-206,460,000	-142,929,000	-107,657,000	-142,799,000	-63,251,000	-66,267,000	-25,533,000	-18,833,000	-26,591,000	46,716,000	34,503,000	-60,410,000	-12,128,000	-123,825,000	-19,685,000	24,009,000	-31,512,000	7,685,000	49,895,000	30,176,000	11,105,000	44,689,000	60,360,000	59,505,000	18,026,000	467,000	66,353,000	-99,629,000	-141,206,000	33,643,000	-52,278,000	37,375,000	32,559,000	-89,895,000	-31,502,000	6,394,000	-15,192,000	-38,382,000	27,611,000	-8,151,000	-69,391,000	-34,557,000	-223,000		50,054,000	8,720,000	29,271,000	7,122,000	4,904,000	9,909,000	-24,954,000	-44,038,000	21,257,000	-31,444,000	32,524,000	6,738,000	-29,639,000	-24,121,000	10,953,000	-179,000			72,000
cash flows from financing activities:
payments for repurchases of common stock	-301,924,000	-283,934,000	-190,412,000	-11,927,000	-264,319,000	-185,375,000	-209,296,000	-216,843,000
proceeds from issuance of common stock under the equity incentive plans and stock purchase plan
taxes paid related to net share settlement of equity awards	-40,502,000	-22,516,000	-16,445,000	-2,166,000	-13,026,000	-6,988,000	-5,986,000	-9,747,000	-10,832,000	-2,557,000	-7,209,000	-4,927,000	-6,478,000	-4,686,000	-24,059,000	-5,636,000	-3,972,000	-5,441,000	-23,898,000	-5,179,000	-19,148,000	-1,793,000	-6,535,000	-935,000	-854,000	-1,580,000	-4,369,000	-229,000	-847,000	-2,129,000	-3,551,000	-681,000	-788,000	-1,543,000
net cash from financing activities	-316,343,000	-294,823,000	-188,034,000	5,696,000	-262,422,000	-184,048,000	-206,173,000	-219,673,000	-124,792,000	4,586,000	-2,003,000	-2,038,000	4,422,000	205,000	-17,994,000	-2,881,000	8,724,000	-2,650,000	-18,694,000	-3,435,000	-5,148,000	2,145,000	-3,000,000	3,274,000	7,053,000	5,226,000	-1,144,000	3,915,000	7,174,000	-254,000	-713,000	2,871,000	-100,218,000	-71,868,000	17,163,000	-45,000	2,649,000	37,000	7,416,000	149,438,000	-3,890,000	-217,000	130,000	-374,000	449,000	65,287,000	-214,000	-789,000	109,000	-10,775,000	-371,000	415,924,000	-578,000	63,453,000	-155,000	1,639,000	6,640,000	179,389,000	-25,550,000	-2,842,000	162,029,000	-2,376,000	-24,873,000	-3,657,000	-1,531,000	-3,928,000	-3,676,000	-4,480,000	12,413,000	-3,627,000	12,073,000	70,354,000	1,139,000	682,000	101,915,000	-2,194,000	8,569,000	1,054,000	5,905,000	47,477,000	42,985,000	4,566,000	34,224,000				11,626,000
net decrease in cash and cash equivalents	-19,319,000	-33,622,000	-40,972,000	59,887,000																												14,145,000																																																		-16,721,000
cash and cash equivalents at beginning of period	0	217,374,000	0	0	0	262,994,000	0	0																												0	0	141,634,000		0	0	80,395,000		0	0	103,978,000		0	0	170,069,000
cash and cash equivalents at end of period	-19,319,000	183,752,000	-40,972,000	59,887,000	-61,102,000	259,561,000	-133,865,000	-67,621,000																												-18,608,000	-147,055,000	276,882,000		83,693,000	-23,038,000	84,987,000		-47,275,000	-10,199,000	157,539,000		-39,758,000	-39,458,000	171,232,000
supplemental cash flow disclosures:
non-cash operating activities:
right-of-use assets obtained in exchange for lease obligations			0	0			3,011,000	28,000			33,977,000	1,595,000			0	0	0	4,893,000	2,193,000	0	1,248,000	576,000
proceeds from issuance of common stock under the equity incentive plans		11,627,000
impairment of long-lived assets			153,000
deferred taxes														15,318,000	14,164,000	9,565,000	26,188,000	-3,388,000	-538,000	-6,990,000	12,665,000	10,128,000
trade receivable
proceeds from issuance of common stock under the equity incentive plan and stock purchase plan			18,823,000	19,789,000
cash paid for taxes
impairment of right-of-use assets
non-cash investing activity:
unpaid liabilities incurred for purchases of in-process research and development technology
depreciation				7,454,000	7,329,000	6,378,000	6,526,000	6,296,000	6,040,000	6,855,000				4,490,000	1,931,000	4,804,000	3,668,000	3,227,000	2,410,000	2,355,000	2,201,000	2,175,000
purchases of investments					-108,686,000	-138,468,000	-78,621,000	-182,519,000	-329,491,000	-311,837,000	-371,305,000	-387,320,000	-355,546,000	-336,545,000	-279,791,000	-388,474,000	-357,291,000	-331,612,000	-203,294,000	-433,821,000	-181,649,000	-251,505,000	-294,984,000	-369,430,000	-278,399,000	-239,869,000	-189,528,000	-141,292,000	-110,475,000	-116,537,000	-71,044,000	-93,237,000	-30,315,000	-124,494,000	-110,678,000	-59,113,000	-150,161,000	-49,235,000	-24,300,000	-73,475,000	-32,935,000	-13,282,000	-10,291,000	-26,957,000	-46,343,000	-35,937,000	-13,207,000	-29,017,000	-51,594,000	-96,157,000
proceeds from maturities and sales of investments					215,278,000	268,452,000	153,493,000	311,077,000	263,143,000	310,769,000	237,990,000	326,412,000	232,741,000	267,615,000	282,696,000	381,732,000	306,657,000	407,424,000		232,351,000	261,887,000	287,086,000
proceeds from issuance of common stock under equity incentive plans						8,315,000				7,143,000		2,889,000	10,900,000	4,891,000			12,696,000	2,791,000				3,938,000
net increase in cash and cash equivalents						-3,433,000	-133,865,000																											31,493,000	40,467,000			135,248,000	-4,008,000	83,693,000	-23,038,000	4,592,000			-10,199,000	53,561,000	11,962,000			1,163,000	-138,736,000			-3,791,000	8,046,000	-9,069,000	-126,771,000	104,611,000	2,098,000	-61,861,000							183,468,000			-13,574,000	-5,869,000			20,470,000	67,669,000	-15,174,000	-54,084,000	43,630,000	6,461,000	-14,811,000
deferred revenue									162,000	-707,000	647,000	-1,299,000	-662,000	-1,169,000	-426,000	2,088,000	-4,076,000	13,422,000	-5,063,000	-5,647,000	809,000	8,850,000					1,819,000	-7,458,000	8,562,000	-2,652,000	-6,965,000	-7,449,000	-6,980,000	35,139,000	5,247,000	56,043,000	-3,333,000	198,802,000	1,000	0	-7,000	-2,576,000	1,264,000	192,000	-116,000	-207,000	433,000	-490,000	-7,704,000	-7,110,000	-7,814,000	-7,813,000	-7,813,000	-18,480,000	-69,366,000	-124,666,000	-25,099,000	-25,397,000	35,256,000	-42,911,000	-8,910,000	-26,380,000	-30,829,000	105,768,000	14,195,000	-3,357,000	189,116,000	-27,019,000	-27,537,000	-1,780,000	233,000	-14,168,000	-24,778,000	42,832,000	41,780,000	-12,712,000	-16,354,000	26,753,000	12,873,000	-9,222,000	18,102,000	6,261,000
proceeds from issuance of common stock under equity incentive and stock purchase plans							9,109,000	6,917,000							6,065,000				5,204,000	1,744,000
net increase in cash, cash equivalents and restricted cash equivalents										39,402,000					65,403,000	59,187,000	119,380,000	99,149,000
cash, cash equivalents and restricted cash equivalents at beginning of period										502,677,000	0	0	0	663,891,000	0	0	0	320,772,000
cash, cash equivalents and restricted cash equivalents at end of period										542,079,000	-174,091,000	39,082,000	-99,590,000	737,276,000	65,403,000	59,187,000	119,380,000	419,921,000
non-cash investing activities:
accounts receivable for unsettled investment sales
net increase in cash, cash equivalents, and restricted cash equivalents												39,082,000	-99,590,000	73,385,000
unpaid liabilities incurred for purchases of property and equipment												-1,927,000			-2,404,000	18,000			-1,000	39,000	323,000	481,000
unpaid liabilities incurred in asset acquisition												0			-5,000,000	0
unpaid liabilities incurred for unsettled investment purchases
proceeds from sale of property and equipment																											0				150,000	0	10,000	4,000	5,000	-20,000	5,000	107,000	46,000	5,000	656,000	639,000	106,000	5,000	5,000	276,000	103,000													11,000	-7,000	175,000
proceeds from sales and maturities of investments
net increase in cash, cash equivalents and restricted cash																				-193,097,000	169,803,000	90,839,000		-127,572,000	-4,148,000	59,162,000	-39,352,000	105,216,000	15,676,000	46,021,000
cash, cash equivalents and restricted cash at beginning of period																				0	0	268,137,000		0	0	315,875,000	0	0	0	188,314,000
cash, cash equivalents and restricted cash at end of period																				-193,097,000	169,803,000	358,976,000		-127,572,000	-4,148,000	375,037,000	-39,352,000	105,216,000	15,676,000	234,335,000
unpaid liabilities incurred to acquire investments
principal repayments of debt
supplemental cash flow disclosure:
cash paid for interest
non-cash activities:
property and equipment deemed to have been acquired in build-to-suit lease
401(k) matching contributions made in common stock																								528,000	1,082,000	2,469,000	464,000	509,000
amortization and other changes in right-of-use assets																								704,000
deferred income taxes																								23,272,000
gain on other equity investments																								0			0	0	0	-209,000	0
accretion of investments, net and other																								-1,051,000	-1,504,000	-1,415,000
other receivables																								-1,192,000	-5,080,000	8,741,000																					1,230,000	-962,000	-344,000	-1,114,000	-44,000	-424,000	-364,000	27,870,000	-25,536,000	1,709,000	-592,000	125,000	1,410,000	-1,278,000	1,062,000	4,774,000	-470,000	-4,333,000	-1,447,000	-2,255,000	434,000	184,000	2,686,000	-3,103,000	-743,000	-901,000	957,000	18,385,000	-18,674,000	-2,151,000	4,422,000	1,313,000	-454,000	-2,163,000	8,216,000	-8,400,000			1,073,000	792,000
current portion of unbilled collaboration revenue																								-490,000
prepaid expenses and other current assets																								-1,643,000	1,299,000	871,000	500,000	-1,952,000	-3,477,000	1,900,000	-738,000	-3,579,000	1,930,000	-881,000	1,732,000	-2,491,000	134,000	-985,000								-359,000	2,529,000	-1,719,000	4,981,000	-4,757,000	128,000	-1,638,000	14,000	-268,000	12,075,000	-2,007,000	1,764,000	-1,279,000	2,891,000	-1,528,000	1,974,000	-3,403,000	-4,429,000	-1,739,000	-430,000	-740,000	-953,000	1,441,000	-512,000	-1,538,000	708,000	-277,000	-2,481,000	-915,000	1,418,000	-1,349,000	-1,200,000	486,000
other long-term assets																								-1,505,000	65,000	-4,854,000	-544,000	-545,000	349,000	-346,000	-259,000	170,000	538,000	-19,000
accounts payable																								-2,731,000	1,317,000	-1,294,000	2,104,000	287,000	-1,352,000	-183,000	3,587,000	-1,049,000	2,388,000	-1,916,000
accrued compensation and benefits																								7,569,000	1,594,000	-9,592,000	4,859,000	5,745,000	782,000	-317,000	1,159,000	4,359,000	1,065,000	-5,844,000
accrued clinical trial liabilities																								6,621,000	654,000	4,824,000	-727,000	2,157,000	1,450,000	-4,498,000	3,668,000	1,501,000	202,000	347,000
rebates and fees due customers																								-491,000	-2,435,000	4,754,000	3,265,000
accrued collaboration liability																								126,000	291,000	137,000	-978,000								-18,710,000	1,717,000	2,319,000	3,736,000
current and long-term deferred revenue																								-1,064,000	5,969,000	-1,313,000
long-term portion of lease liabilities																								-690,000	-740,000	7,517,000	-251,000
other current and long-term liabilities																								8,231,000	-13,460,000	21,169,000	5,548,000	-13,485,000	8,631,000	1,533,000	-2,289,000	4,742,000	-3,469,000	10,926,000
purchases of property and equipment																								-2,059,000	-1,209,000	-2,307,000					-17,694,000	-1,137,000	-1,504,000	-808,000	-587,000	-33,000	-401,000	-682,000	-333,000	-20,000	-63,000	-31,000	-22,000	-108,000	40,000	-384,000	-92,000	-677,000	-673,000	-729,000	-1,189,000	-1,019,000	-437,000	-72,000	-279,000	-144,000	-163,000	-405,000	-330,000	-650,000	-579,000	-252,000	-4,316,000	-750,000	-444,000	-398,000	-1,207,000	-2,391,000	-6,171,000	-5,363,000	-3,249,000	-4,749,000	-5,761,000	-3,640,000	-3,273,000	-1,540,000	-4,740,000	-2,057,000	-3,238,000	-2,859,000	-4,274,000	-3,986,000
proceeds from maturities of investments																								163,628,000	128,971,000	129,820,000	49,622,000	91,256,000	52,444,000	87,504,000	70,255,000	65,442,000	78,386,000	122,507,000	50,850,000	42,295,000	28,232,000	30,108,000	48,595,000	35,903,000	40,028,000	54,410,000	40,385,000	31,248,000	90,947,000	90,311,000	73,701,000	41,581,000	52,793,000	157,096,000
proceeds from sale of investments																								1,401,000	6,978,000	4,699,000	1,000	1,698,000	3,999,000	6,238,000	0	0	0	37,294,000	0	2,249,000	0	17,000
proceeds from other equity investments																								0			0	0	0	209,000	0
proceeds from exercise of stock options																								4,221,000	3,773,000	6,817,000	1,686,000	3,840,000	4,675,000	1,875,000	1,023,000	3,552,000	3,305,000	9,675,000	16,031,000	7,089,000
proceeds from employee stock purchase plan																								0			1,552,000	0			1,815,000	0			1,708,000	0			294,000	0			509,000	1,000			535,000	0			389,000	1,000			747,000	0			1,010,000	0			1,676,000	0							1,825,000	1,000			1,516,000	0			1,083,000	0			978,000	0			0
principal payments on financing lease obligation																								-12,000	-11,000	-11,000
amortization and other right-of-use assets																										-7,730,000
unbilled collaboration revenue																										-7,753,000				-38,014,000
amortization of right-of-use assets
loss on extinguishment of debt																															0	0			128,000
amortization of debt discounts and debt issuance costs																															0	0	93,000	89,000
interest paid in kind																															0
payments on conversion of convertible notes																																			-1,000
changes in assets and liabilities:
trade and other receivables																												70,324,000	-75,214,000	-10,755,000	8,402,000	-46,660,000	-9,122,000	6,541,000	48,921,000	-73,562,000	-7,423,000	-4,938,000	-1,680,000	288,000	-546,000	1,292,000	-160,000	312,000	-577,000	-516,000
operating lease right-of-use assets
purchases of property and equipment and other																												-15,221,000	-12,235,000	-2,947,000
supplemental cash flow disclosure - non-cash investing and financing activity:
property and equipment deemed to have been acquired under build-to-suit lease
unpaid liabilities incurred to acquire property and equipment
changes in warrant fair value
purchase of restricted cash and investments																															-4,500,000	-5,000,000	-2,646,000	-3,504,000	-4,500,000	0	-2,146,000	-2,004,000	-3,034,000	1,568,000	-1,500,000	-2,684,000	41,000	-3,541,000	-4,139,000	-504,000	-2,300,000	-1,000	-3,280,000	-504,000
proceeds from maturities of restricted cash and investments																															4,000,000	5,000,000	2,146,000	3,504,000	4,500,000	0	646,000	2,004,000	3,035,000	4,507,000	1,499,000	10,748,000	-43,000	9,620,000	4,179,000	6,598,000	1,300,000	6,100,000	3,221,000	6,647,000
proceeds from issuance of common stock																																						37,000	-2,000				-3,000	0	0	75,646,000					0					0	30,000	179,347,000																						49,614,000	0	8,854,000					8,247,000
cash and cash equivalents at beginning of year																																	0	151,686,000
cash and cash equivalents at end of year																																	-47,967,000	183,179,000
stock-based compensation expense																																5,289,000	5,027,000	4,713,000	4,566,000	3,603,000	3,558,000	11,185,000	6,557,000	12,026,000	1,734,000	1,660,000	1,552,000	714,000	3,982,000	3,758,000	3,528,000	2,898,000	2,926,000	2,679,000	2,611,000	1,900,000	1,990,000	2,332,000	2,690,000	2,974,000	2,832,000	3,603,000	4,368,000	5,463,000	4,755,000	6,526,000	5,394,000	5,939,000	6,481,000	5,092,000	5,826,000	5,788,000	5,619,000	5,674,000	5,218,000	5,229,000	5,178,000	4,543,000	4,458,000	4,076,000	4,443,000	4,636,000
repayment of convertible notes and term loan payable																																0
payment on conversion of convertible notes
construction-in-progress deemed to have been acquired under build-to-suit lease																																0
issuance of common stock in settlement of convertible notes
accrual of interest paid in kind																																	-13,893,000	2,068,000	2,069,000	2,031,000	1,972,000	1,936,000	1,927,000
gain on sale of other equity investments
proceeds from sale of other equity investments
principal payments on debt																																		-80,000,000					0	0	-4,164,000	-217,000	-376,000	-375,000	-479,000	-10,479,000	-796,000	-792,000	-791,000	-10,791,000
cash flows from operating activities:
gain on sale of business and other equity investment																																							-17,000
changes in the fair value of warrants																																											76,000	-62,000
proceeds from sale of business and other equity investments
redemption of convertible notes
accretion of debt discount and debt issuance costs																																				-2,417,000
gain on sale of equity investment																																									0	-95,000
change in the fair value of warrants																																								0	0	549,000
other long term assets																																				436,000	-142,000	241,000
accounts payable, accrued compensation and benefits, and other accrued liabilities																																				4,527,000	8,956,000	5,333,000
clinical trial liabilities																																				-794,000	-454,000	-1,936,000		-2,784,000	1,596,000	-10,569,000		3,735,000	2,249,000	4,160,000
other long-term liabilities																																				-322,000	-235,000	-258,000	-306,000	-464,000	-615,000	-288,000	-671,000	-277,000	-250,000	-229,000	-1,160,000	-156,000	-231,000	-143,000	-1,512,000	210,000	-199,000	-87,000	-404,000	-198,000	-328,000	-232,000	-7,064,000	-227,000	-877,000	-152,000	-6,581,000	402,000	402,000	483,000	-4,718,000	1,084,000	499,000	831,000	505,000	1,164,000	1,667,000	1,097,000	1,310,000	1,326,000	1,670,000	1,709,000	1,725,000	1,801,000	1,341,000	1,612,000	1,157,000	618,000	550,000	550,000	250,000
proceeds from sale of equity investments
supplemental cash flow disclosure - non-cash financing activity:
restructuring liability																																					130,000	-1,057,000	-1,449,000	-2,410,000	-297,000	-3,024,000	403,000	298,000	-1,762,000	-1,241,000	-430,000	-1,971,000	-971,000	-2,378,000	8,733,000	-1,494,000	-130,000	-1,865,000	3,583,000			-1,478,000
proceeds from equity investment
accretion of debt discount																																						5,285,000	4,840,000	5,303,000	7,216,000	7,675,000	7,708,000	7,510,000	7,328,000	6,988,000	6,845,000	6,652,000	6,479,000	6,314,000	6,128,000	4,147,000	2,284,000	2,193,000	2,089,000	2,084,000	492,000	3,324,000
accounts payable, accrued compensation, and other accrued liabilities																																							-1,114,000	-567,000	3,821,000	-3,416,000		-6,695,000	5,349,000	-10,254,000
clinical trial liability																																															-84,000	5,636,000
proceeds from sale of business and other equity investment																																							0
proceeds from exercise of stock options and warrants																																							7,124,000				0	0	0	120,000	47,000	3,000	6,000	16,000	28,000				731,000	4,079,000	3,832,000	3,794,000	1,630,000	50,000	133,000	871,000	269,000	2,000	0	2,000	11,000	5,000	288,000	6,000	480,000	1,429,000	3,211,000	3,181,000		159,000	798,000	1,562,000
non-cash financing activity:
issuance of warrants in connection with amendment to convertible notes																																											0	0	0	2,762,000
restructuring charge for property and equipment
proceeds from sale of equity investment																																									0	95,000
gain on sale of business																																											0																	0	-3,297,000	-4,500,000
other assets																																														-5,000					17,000	-1,759,000	-108,000	-116,000	-296,000	469,000	118,000	114,000	-87,000	-19,000	-1,712,000	11,000	5,313,000	370,000	371,000	370,000	416,000	345,000	-3,631,000	95,000	427,000	-118,000	-486,000	2,000	-30,000	702,000	106,000	-134,000	-11,000	67,000	11,000	-1,089,000					-3,000
accounts payable and other accrued liabilities																																															9,343,000	-1,031,000	5,851,000	-5,472,000																						7,269,000
proceeds from sale of business																																											0																			4,500,000
proceeds from debt issuance
gain on warrants																																														-1,739,000
restructuring (credit) charge for property and equipment																																																			-63,000	38,000	16,000	-195,000
gain on sale of property and equipment
gain on sale of businesses
proceeds from sale of businesses
issuance of common stock for settlement of convertible loan, including accrued interest
restructuring credit for property and equipment
net gain on sale of property and equipment
accounts payable and other accrued expenses																																																				3,079,000	2,937,000	-2,736,000	-3,330,000	-2,411,000	-2,719,000	2,905,000	-8,234,000	2,416,000	-9,776,000	6,150,000	7,703,000	4,401,000	3,925,000	-7,021,000	1,173,000	3,796,000	-303,000	2,297,000				6,667,000	8,100,000	2,258,000	614,000	1,192,000	2,593,000	1,225,000	3,326,000	-6,789,000
proceeds from sales of property and equipment																																																				18,000	12,000	847,000
proceeds on sale of business																																																											400,000	0
increase in restricted cash and investments																																																												0				0	108,000	-837,000
proceeds from maturities of marketable securities																																																				95,219,000	80,789,000	60,315,000	7,556,000	50,837,000	39,689,000	26,718,000	32,469,000	23,070,000	38,059,000	33,971,000	43,769,000	635,000	2,425,000	2,938,000	9,000	7,871,000	9,002,000	34,299,000	15,152,000	49,732,000	57,095,000	34,360,000	8,133,000	26,315,000	19,750,000	45,443,000
proceeds from convertible notes
proceeds from note payable and bank obligations																																																								0				0
principal payments on notes payable and bank obligations																																																				-788,000	-1,648,000	-1,646,000	-1,631,000	-2,440,000	-798,000	-3,752,000	-30,690,000	-2,892,000	-2,734,000	-3,247,000	-31,820,000	-3,659,000	-3,656,000	-3,930,000	-5,699,000	-4,485,000	-3,636,000	-3,633,000	-2,857,000	-2,973,000	-3,813,000	-2,499,000			-33,488,000	-2,842,000	-1,720,000	-2,179,000	-1,724,000	-3,678,000
cash and cash equivalents, at beginning of period																																																				0	0	74,257,000		0	0	97,440,000		0	0	86,796,000		0	0	247,698,000		0	0	135,457,000		0	0	123,369,000		-15,143,000	0	96,471,000		0	0	78,105,000		0	0	111,828,000	0
cash and cash equivalents, at end of period																																																				240,665,000	-2,326,000	70,466,000		-9,069,000	-126,771,000	202,051,000		-61,861,000	98,911,000	58,292,000		17,658,000	-48,513,000	201,425,000		-10,817,000	-46,836,000	121,883,000		35,719,000	-38,232,000	143,839,000		-30,317,000	-54,084,000	140,101,000		-14,811,000	43,437,000	61,384,000		9,069,000	-41,399,000	80,323,000	-13,516,000
decrease in restricted cash and investments																																																								0	0	2,200,000
proceeds from issuance of common stock, net of offering costs																																																					46,000	64,990,000
proceeds from exercise of stock options and warrants, net of repurchases																																																					197,000	109,000
consolidated net income																																																							46,296,000	77,865,000			-17,865,000	-8,603,000	-22,613,000	-43,249,000	-28,834,000	-25,445,000	-46,942,000	-38,336,000
impairment of property and equipment, net of proceeds from sales
loss on deconsolidation of symphony evolution, inc.																																																															0	0
purchases of investments held by symphony evolution, inc.																																																															0	0	-13,000	-36,000	-106,000	-133,000	-173,000	-295,000	-444,000	-556,000	-611,000	-669,000	-745,000	-810,000	-40,440,000	-343,000	-351,000	-325,000
proceeds on sale of investments held by symphony evolution, inc.																																																															0	0	2,339,000	2,158,000	3,876,000	4,036,000	5,370,000	3,657,000	8,241,000	6,534,000	6,854,000	4,804,000				4,102,000	3,854,000
proceeds on sale of property and equipment
proceeds on sale of businesses
decrease (increase) in restricted cash and investments
proceeds from sale of marketable securities																																																											0	0	0	12,780,000	-7,027,000					27,171,000
proceeds from issuance of stock, net of offering costs
proceeds from notes payable and bank obligations																																																																			0	0							12,367,000	0	0	2,424,000	6,107,000	0
repayments, net from deconsolidation of symphony evolution, inc.																																																															0	0
cash and cash equivalents, at beginning of year
cash and cash equivalents, at end of year
impairment of assets due to restructuring																																																								-131,000	388,000	122,000			7,000	2,474,000
restructure liability
proceeds from sales of marketable securities
impairment of assets																																																											846,000
gain on sale of plant trait business and artemis pharmaceuticals
warrants issued in conjunction with deerfield financing agreement																																																																			0	0
accretion of deerfield implied interest
accrued restructuring liability
net decreases in cash and cash equivalents																																																														-28,504,000		17,658,000	-48,513,000	-46,273,000
amortization of intangibles																																																																										72,000	98,000	210,000	240,000	272,000	271,000	271,000	272,000	272,000	278,000	168,000	167,000	166,000	166,000
proceeds on sale of plant trait business
proceeds on sale of artemis pharmaceuticals
(increase)/decrease in restricted cash and investments
proceeds from the issuance of common stock, net of offering costs
effect of foreign exchange rates on cash and cash equivalents																																																																															-5,000	-4,000	-173,000	45,000					70,000
non-cash investing and financing activities:
loss attributed to noncontrolling interest																																																																			-2,796,000	-2,681,000	-3,343,000	-3,896,000	-2,408,000	-8,184,000	-7,460,000	-6,589,000	-6,863,000	-5,546,000	-5,770,000	-3,518,000	-4,891,000	-5,086,000
proceeds from sale of equipment																																																																											6,000	0
proceeds on sale of marketable securities
net cash provided (used) in investing activities
payments on capital lease obligations																																																																											0	0	-8,000	-90,000	-249,000	-384,000	-634,000	-664,000
proceeds from purchase of noncontrolling interest by preferred shareholders in symphony evolution, inc., net of fees																																																																											0	0			0	0
warrants issued in conjunction with the symphony evolution, inc. financing
changes in restricted cash and investments																																																																				840,000	-361,000	1,905,000		840,000	990,000	-273,000
proceeds from sale of stock, net of offering costs
proceeds from employee stock purchase plans																																																																				0
effect of foreign exchange rate changes on cash and cash equivalents																																																																								-183,000	-11,000	-58,000		14,000	37,000	18,000
loss on the sale of equipment
change in restricted cash and investments																																																																											1,586,000	-216,000	1,119,000	559,000	840,000	1,231,000	727,000	560,000
amortization of intangible assets																																																																								51,000
income from the sale of equipment																																																																								7,000	1,000	5,000
proceeds from purchase of noncontrolling interest by preferred stockholders in symphony evolution, inc.
warrants issued in conjunction with the symphony evolution, inc. transaction																																																																												0			5,684,000	0
proceeds from maturities of long term marketable securities																																																																										2,020,000
acquired in-process research and development																																																																																			25,981,000	0
cash paid for acquisitions, net of cash acquired
repayment of notes from stockholders																																																																																			0	0	0	53,000	74,000
gain on the sale of equipment																																																																												-3,000				0	-16,000	-122,000
proceeds from sale of investments held by symphony evolution, inc.																																																																												6,106,000
principal payments on notes and bank obligations
related-party receivables																																																																															0	3,000	15,000	27,000	28,000	40,000			65,000
stock compensation expense																																																																																28,000	23,000	-16,000			42,000	33,000
non-cash portion of restructuring charge
prepaid expense and other current assets																																																																																-1,249,000	-669,000	-925,000
cash received from acquisition, net of cash paid
proceeds on sale of equipment																																																																																0	1,000	152,000
proceeds from maturities of short-term investments																																																																																10,618,000	35,026,000	35,512,000	19,482,000	64,596,000	24,773,000	29,307,000	52,017,000
purchases of short-term investments																																																																																-41,092,000	-15,596,000	-21,285,000
proceeds from exercise of stock options, net of repurchases																																																																																426,000	609,000	54,000		542,000	1,268,000	721,000	8,000
income from discontinued operations
proceeds from sale of investments before maturity
proceeds from bank obligations																																																																																			4,849,000	7,457,000			5,933,000
property and equipment acquired under capital leases
stock compensation expense, net of reversals																																																																																							167,000
other current assets
cash from acquisition																																																																																				0
changes in restricted cash
accrued merger and acquisition costs
change in restricted cash
principal payments on capital lease obligations

We provide you with 20 years of cash flow statements for Exelixis stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Exelixis stock. Explore the full financial landscape of Exelixis stock with our expertly curated income statements.

The information provided in this report about Exelixis stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.